言語を選択
新規登録

HLA-A*0201 & B2M & CMV pp65

お問い合わせ

HLA-A*0201 & B2M & CMV pp65バックグランド

Cytomegalovirus (Cytomegalovirus) is a herpes viral DNA virus. Human cytomegalovirus (HCMV) can only infect humans and multiply in humans. The antibodies. After primary infection with CMV, the body can produce specific antibodies and killer T lymphocytes to activate NM cells. The antibody has limited CMV replication ability and has a certain resistance to reinfection of the same strain, but cannot resist the activation of antibody-dependent virus and the exogenous infection of other different strains of CMV. However, specific killer T lymphocytes and antibody-dependent cytotoxic cells can exert the greatest antiviral effect. The Human HLA-A*0201 CMV (NLVPMVATV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and NLVPMVATV peptide of the CMV.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
EbselenSPI-1005; SPI-3005; PZ-51; DR-3305Phase 3 ClinicalSound Pharmaceuticals Inc, Daiichi Sankyo Co LtdTinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders
詳細
OlgotrelvirSTI1558; STI-1558Phase 3 ClinicalTexas A&M UniversityCoronavirus Disease 2019 (COVID-19)
詳細
S-892216S-892216Phase 3 ClinicalShionogi & Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
ibuzatrelvirPF-07817883Phase 3 ClinicalPfizer IncCoronavirus Disease 2019 (COVID-19)
詳細
MprosevirWPV-01Phase 3 ClinicalWestlake UniversityCoronavirus Disease 2019 (COVID-19)
詳細
QLS-1128QLS-1128Phase 3 ClinicalQilu Pharmaceutical Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
MIR-19MIR-19Phase 3 ClinicalSt. Petersburg Scientific Research Institute of Vaccines and SeraCoronavirus Disease 2019 (COVID-19)
詳細
BofutrelvirFB-2001; DC-402234Phase 3 ClinicalShanghai Institute Of Materia Medica, Chinese Academy Of SciencesCoronavirus Disease 2019 (COVID-19)
詳細
SHEN-211SHEN-211; SHEN211Phase 2 ClinicalHubei JKT BioPharma Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
HS-10517HS-10517; HS10517Phase 2 ClinicalJiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
EDP-235EDP-235Phase 2 ClinicalEnanta Pharmaceuticals IncCoronavirus Disease 2019 (COVID-19)
詳細
TollovirPhase 2 ClinicalTodos Medical LtdCoronavirus Disease 2019 (COVID-19)
詳細
PentarlandirSNB-01; SNB-011Phase 2 ClinicalSyneurx International (Taiwan) CorpCoronavirus Disease 2019 (COVID-19)
詳細
NirmatrelvirPF-07321332Phase 2 ClinicalPfizer AsCoronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency
詳細
CDI-988CDI988Phase 1 ClinicalCocrystal Pharma IncCoronavirus Disease 2019 (COVID-19)
詳細
PomotrelvirPBI-0451Phase 1 ClinicalPardes Biosciences IncCoronavirus Disease 2019 (COVID-19)
詳細
CMX-990CMX-990; CMX990Phase 1 ClinicalThe Scripps Research Institute IncCoronavirus Disease 2019 (COVID-19)
詳細
WPV-02WPV-02; WPV02Phase 1 ClinicalWestlake Pharmaceuticals (Hangzhou) Co LtdVirus Diseases
詳細
ISM-3312ISM-3312Phase 1 ClinicalInsilico Medicine LtdCoronavirus Disease 2019 (COVID-19)
詳細
ABBV-903ABBV-903Phase 1 ClinicalAbbvie Inc
詳細
SYH-2055SYH-2055Phase 1 ClinicalCSPC Pharmaceutical Group LtdCoronavirus Disease 2019 (COVID-19)
詳細
AtilotrelvirGST-HG171Phase 1 ClinicalFujian Guangsheng Zhonglin Biotechnology Co LtdCoronavirus Disease 2019 (COVID-19)
詳細
ALG-097558ALG-097558Phase 1 ClinicalRega Institute, Ku Leuven, Aligos Therapeutics IncCoronavirus Disease 2019 (COVID-19)
詳細
ASC11ASC-11Phase 1 ClinicalAscletis Pharma IncCoronavirus Disease 2019 (COVID-19)
詳細
LufotrelvirPF-07304814Phase 1 ClinicalPfizer IncCoronavirus Disease 2019 (COVID-19); Virus Diseases
詳細
TravatrelvirTRX-01ClinicalTraws Pharma IncCoronavirus Disease 2019 (COVID-19)
詳細
GS221GS-221; GS221ClinicalGrand Pharmaceutical （China） Co LtdCoronavirus Disease 2019 (COVID-19)
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Atilotrelvir/RitonavirApprovedFujian Guangsheng Zhonglin Biotechnology Co Ltd泰中定Mainland ChinaCoronavirus Disease 2019 (COVID-19)Fujian Guangsheng Zhonglin Biotechnology Co Ltd2023-11-23Coronavirus Disease 2019 (COVID-19)
詳細
SimnotrelvirSIM-0417; SSD-8432; VV-934ApprovedJiangsu Simcere Pharmaceutical Co LtdMainland ChinaCoronavirus Disease 2019 (COVID-19)Jiangsu Simcere Pharmaceutical Co Ltd2023-01-28Coronavirus Disease 2019 (COVID-19)
詳細
LeritrelvirRAY-1216; [14C]RAY1216; [14C]-RAY-1216ApprovedGuangdong Raynovent Biotech Co Ltd乐睿灵Mainland ChinaCoronavirus Disease 2019 (COVID-19)Guangdong Raynovent Biotech Co Ltd2023-03-23Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Hepatic Insufficiency
詳細
Simnotrelvir/RitonavirSIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / RitonavirApprovedShanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Jiangsu Simcere Pharmaceutical Co Ltd, Wuhan Institute Of Virology, Chinese Academy Of Sciences先诺欣Mainland ChinaCoronavirus Disease 2019 (COVID-19)Jiangsu Simcere Pharmaceutical Co Ltd2023-01-28Renal Insufficiency; Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency
詳細
Ensitrelvir Fumaric AcidS-217622ApprovedShionogi & Co Ltd, Hokkaido UniversityXocovaJapanCoronavirus Disease 2019 (COVID-19)Shionogi & Co Ltd2022-11-22Renal Insufficiency; Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency
詳細
Nirmatrelvir/RitonavirApprovedPfizer IncPaxlovidEUCoronavirus Disease 2019 (COVID-19)Pfizer Europe Ma Eeig2022-01-28Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome
詳細
  • お問い合わせ
  • 市販薬剤に関する情報
  • 治験薬に関する情報
共有：

採用情報法的規制サイトマッププライバシーポリシー利用規約
ウェブサイトに関するフィードバック
お問い合わせ

お問い合わせ
グローバル：+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8